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POINT OF VIEW
Timing of Deep Brain Stimulation in
Parkinson Disease: A Need for
Reappraisal?
Ruth-Mary deSouza, MRCS,1 Elena Moro, PhD, MD,2 Anthony E. Lang, FRCP,
MD,3 and Anthony H. V. Schapira, DSc, MD, FRCP, FMedSci1
We review the current application of deep brain stimulation (DBS) in Parkinson disease (PD) and consider the evi-
dence that earlier use of DBS confers long-term symptomatic benefit for patients compared to best medical therapy.
Electronic searches were performed of PubMed, Web of Knowledge, Embase, Cochrane Database of Systematic
Reviews, and Cochrane Central Register of Controlled Trials to identify all article types relating to the timing of DBS
in PD.
Current evidence suggests that DBS is typically performed in late stage PD, a mean of 14 to 15 years after diagnosis.
Current guidelines recommend that PD patients who are resistant to medical therapies, have significant medication
side effects and lengthening off periods, but are otherwise cognitively intact and medically fit for surgery be consid-
ered for DBS.
If these criteria are rigidly interpreted, it may be that, by the time medical treatment options have been exhausted,
the disease has progressed to the point that the patient may no longer be fit for neurosurgical intervention. From
the evidence available, we conclude that surgical management of PD alone or in combination with medical therapy
results in greater improvement of motor symptoms and quality of life than medical treatment alone. There is evi-
dence to support the use of DBS in less advanced PD and that it may be appropriate for earlier stages of the disease
than for which it is currently used. The improving short and long-term safety profile of DBS makes early application a
realistic possibility.
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Parkinson disease (PD) is the second most commonneurodegenerative disease after Alzheimer disease. The
incidence rate of PD is 12 to 20 per 100,000 annually in
Northern Europe.1 It is estimated that there are approxi-
mately 1 million PD sufferers in the USA and 120,000 in
the United Kingdom, 1 in 20 of whom are under the age
of 40 years.2 An analysis of PD epidemiology suggests
that the number of individuals aged >50 years with PD
in the world’s most populated countries will approximately
double to between 8.7 and 9.3 million in 2030.3
In 2007, the global economic cost of PD was esti-
mated to be up to £3 billion (approximately US $4.63
billion) annually.4 Recent reviews and cost analyses
showed the greatest expenditure was on nursing homes
and social care.5–7 Costs increase in later stage PD.8 This
reinforces the notion that despite optimal medical ther-
apy, there remains significant morbidity and disability yet
to be addressed in PD.
The clinical features of PD comprise the well-rec-
ognized motor syndrome and a large number of nonmo-
tor manifestations.9 Medication side effects, psychological
morbidity, poor quality of life, and the burden on carers
are important components that make PD a complex,
chronic, multifaceted disease.
The mainstay of treatment for PD is currently
medical, surgical, and supportive treatment. Among
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surgical treatments, there is currently level 1 evidence
that deep brain stimulation (DBS) of the subthalamic
nucleus (STN) and the globus pallidus internus (GPi) is
effective in improving L-dopa–responsive signs in PD
patients.10–13 Traditionally, DBS has been typically left
until late stage PD, a mean of 14 to 15 years after diag-
nosis,14–16 although this may not necessarily reflect cur-
rent practice. Continued interest in surgical therapies for
PD is encouraged by the increasing awareness of the
adverse effects and limitations of medical therapy for PD
as well as advances in medical imaging and bioengineer-
ing technology. STN DBS received US Food and Drug
Administration approval for use in PD in 2002 and GPi
DBS received it in 2003. Work then centered on finding
the ideal nucleus to target.13–19
The initial criteria of inclusion for DBS have been
relatively strict and include the presence of significant
disability but the absence of cognitive dysfunction.20,21
The UK National Institute for Clinical Excellence
(NICE) guidelines have recommended that PD patients
who are resistant to medical therapies, have severe medi-
cation side effects and lengthening off periods, but are
medically and psychologically fit for surgery, be consid-
ered for DBS.22 If these criteria are rigidly interpreted, it
might be that, by the time medical treatment options
have been exhausted, the disease has progressed to the
point that the patient may no longer be fit enough for
neurosurgical intervention. The 2006 consensus on treat-
ments for PD acknowledged this potentially critical issue
in patient selection, proposing individualized criteria for
selection (disability, quality of life, expectations of func-
tionality, interpersonal relationships), good response to L-
dopa (the only positive predictor of DBS benefit), and
recommended further research into the use of surgery
earlier in the course of PD.23
The purpose of this review is to consider whether
earlier use of DBS confers long-term symptomatic bene-
fit for patients compared to best medical therapy, and to
review the evidence suggesting DBS has a disease-modify-
ing role.
Current Medical Management of PD
Following a diagnosis of PD, NICE considers the man-
agement in 3 main tiers: management of early PD (func-
tional effect of disease apparent), management of late PD
(motor complications), and surgical management.24 The
Movement Disorder Society also used critical appraisal of
the literature to offer guidelines on management of
uncomplicated and complicated PD.25 Combination
therapy is recognized to be a common feature at all
stages. The unmet needs of PD management include
control of nonmotor features, motor complications, and
the development of disease-modifying therapies.26–29
Currently, medical therapy remains the first-line treat-
ment for PD, and DBS should only be considered for
selected patients in whom medical therapy is failing and
its effectiveness is limited by side effects.
Current Use of DBS in PD
The current indications and patient selection criteria for
DBS have recently been reviewed.23,30,31 For DBS to be
considered, most importantly the patient must have do-
pamine-responsive PD. The patient should not have sig-
nificant cognitive dysfunction, and should be emotionally
stable with no active severe psychiatric symptoms. Both
sporadic and genetic PD patients are eligible for DBS.30
Because cognitive, affective, and psychotic symp-
toms are part of the (late) natural history of PD and
medical comorbidities increase with age and debility, it is
possible that by waiting too long to perform DBS we are
turning potential DBS candidates into exclusion
cases.32,33
The benefits of DBS include motor and nonmotor
function attenuation of drug-induced dyskinesias and
improvement in quality of life.10,16,34,35
In terms of motor benefits, DBS reduces off symp-
toms by 60%, rapidly reduces medication-induced dyski-
nesias in STN DBS by 60 to 80% as medication
requirements are less, and improves Unified Parkinson
Disease Rating Scale (UPDRS) scores and self-assessed
quality of life.10,15,34 Although many claims have been
made regarding the relative benefits of STN versus GPi
stimulation, only well-designed studies with homogene-
ous reporting methods of outcomes will enable robust
discrimination of benefit between different DBS sites and
techniques.36 STN DBS was shown in a level 3 study of
30 patients to be associated with maintenance of the
long-term L-dopa response but worsening of the short-
term L-dopa response in advanced PD, a situation mim-
icking early stage PD.37 Long-term data are now emerg-
ing, and indicate that DBS motor benefits are still
clinically apparent at 10 years.19,38,39 The 10-year fol-
low-up of 18 patients showed that STN DBS resulted in
significant improvement in tremor, bradykinesia, and
total motor score but not axial motor function and not
activities of daily living (ADL) scores.39 There are studies
comparing STN and GPi DBS in terms of long-term
benefit. A 5-year prospective study of 35 STN patients
and 16 GPi patients showed STN DBS to be associated
with greater motor benefit than GPi DBS in some
domains (off-medication UPDRS, dyskinesias, and
ADL).19 A randomized trial of 159 patients with PD
showed significant improvements in 36-month motor
UPDRS on-stimulation/on-medication and off-
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stimulation/off-medication, both of which favored GPi,
but there was no difference in overall quality of life
measures at this time point, although dementia rating
scales declined faster in the STN group.17 This study
also showed stability of benefits at 3 years.17 The COM-
PARE trial examined the effects of GPi versus STN DBS
on cognition and mood in 45 patients with a mean PD
duration of 13 years.11 No overall difference was
observed between the groups, but verbal fluency was
worse at 7 months after STN than GPi DBS.11 Both
STN and GPi DBS offer advantages,40 and the differen-
ces between these may only become apparent in studies
with >5 years follow-up postimplantation.19,31,34,41
Studies addressing the effect of DBS on symptoms also
report improvement of nonmotor features of PD such as
pain, akathisia, cognitive function, emotion, ADL, and
autonomic function.42–47
The choice between STN and GPi DBS and
whether unilateral, bilateral, or staged bilateral is based
upon the patient’s individual symptoms and the surgeon’s
experience. There is no level 1 evidence that demonstrates
superiority of either site. There is level 2 and 3 evidence
showing that choice and laterality of site can affect indi-
vidual motor and nonmotor features (for example postural
response, verbal fluency, and quality of life), but no evi-
dence to generate firm recommendations on situations
where STN or GPi would be more effective. A 6-year
multicenter follow-up study showed no difference in effi-
cacy between STN and GPi, but did show a lower inci-
dence of DBS complications in the GPi group.19,48–50
The adverse events associated with DBS are a key
consideration in whether to perform this procedure more
liberally. Side effects can be operation, hardware, or stim-
ulation related (Table 1).51 They can be immediate,
early, or delayed and be motor or nonmotor. The inci-
dence of complications is lower in large centers that spe-
cialize in DBS.51
From a 2011 consensus on DBS in PD, the most
common surgical complications reported in the available
literature were infection (0–15%), bleeding (0–10%),
stroke (0–2%), lead erosion (1–2.5%), lead breakage
(0–15%), lead migration (0–19%), and death (0–
4.4%).30 Hardware complications may necessitate a sec-
ond procedure. Neuropsychiatric adverse effects reported
include severe depression, increased suicide risk,52 apathy,
anxiety,53,54 decreased frontal cognitive function,55 obses-
sive–compulsive disorder, impulse control disorders,
and aggression.56–60 Recent data suggest bilateral STN
stimulation might be associated with some worsening of
motor and cognitive performance on complex dual task
testing, whereas unilateral STN stimulation would not
cause this problem.61 Recent work, investigating the
TABLE 1. Complications of DBS
Operation related Intracerebral hematoma, 0–10%
Chronic subdural hematoma
Incorrect placement of electrodes or leads
Air embolism
Death, 0–4.4%
Complications of anesthesia
Infection (most common complication), up to 15%31
Hardware related Interaction with cardiac pacemakers112
Electrode migration, 0–19%10
Lead fracture, 0–15%
Lead erosion, 1–2.5%
Foreign body reaction
Skin erosion
Interaction with diathermy causing tissue damage
Cognitive decline
Stimulation related Psychiatric disturbance including mania, depression, impulse control disorders,
psychosis, and suicidal ideation
Weight gain
Sensory disturbance
Speech, visual, and auditory disorders including apraxia of eyelid opening
Dyskinesias and dystonia
Reduction in verbal fluency
Percentages are provided where available. See text for details.
DBS5 deep brain stimulation; MRI5magnetic resonance imaging.
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mechanisms of psychiatric symptoms post-DBS using
[11C]-raclopride positron emission tomography (PET)
scans of 12 patient with post–STN-DBS apathy, suggests
that this symptom is associated with dopamine denerva-
tion in the mesolimbic circuits,62 and apathy may be
related at least in part to anti-PD drug reduction and
withdrawal after surgery, rather than the direct effect of
STN DBS. Other DBS-related possible complications in
PD include weight gain63; sleep disorders64; eyelid open-
ing apraxia65; speech, gait, and balance worsening; and
hypersexuality.66 As indicated above, impaired verbal flu-
ency is a known side effect of DBS11 and may be a surgi-
cal effect.67 Clinical effectiveness of DBS may not
translate into a quality of life benefit in older patients.68
DBS in a younger population seems to have a higher
impact on improving their quality of life and helping to
maintain active, independent lifestyles. It is possible that
the incidence of serious adverse events during DBS will
be less in patients with milder PD, who are likely to be
younger with fewer comorbidities.
Evidence Comparing DBS and Medical
Treatments
There have been a number of trials comparing optimal
medical management and DBS (with or without concur-
rent medical management). Three randomized controlled
trials show that STN DBS results in improved patient-
reported quality of life.10,12,69 Significant motor and con-
sequent functional improvement was demonstrated by
surgical patients experiencing greater improvement in
UPDRS scores at 6 months post-DBS than medically
managed patients in a randomized pairs trial of 156
patients who had been on L-dopa for a mean of
13 years.10 The PD SURG randomized open label trial
compared best medical therapy and surgery (either stimu-
lation or lesioning of the STN or the GPi). This
randomized controlled trial of bilateral DBS versus medi-
cal therapy evaluated 255 patients who had taken PD
medications for a mean of 10 to 12 years. After 6 months
of follow-up, those who had DBS showed significant
improvement in motor function, motor side effects, and
quality of life.12 However, quality of life improvement
should be balanced against the incidence of severe sur-
gery-related side effects such as intracranial hemorrhage
and infection, and stimulation-related side effects, such
as worsening of axial signs, particularly speech.12
The economic impact of DBS for PD has been
explored in modeling studies.70 Specific DBS-related
expenses such as equipment, surgical theater time, and
hardware as well as long-term costs such as social care
are relevant.71 Broad assessment tools are necessary for
cost-effectiveness in view of the “acute on chronic”
nature of DBS (ie, combination of initial surgical costs
and long-term social care costs).71 Comparative cost
analyses of DBS and optimal medical therapy concluded
that DBS may be more efficient clinically on the basis of
UPDRS scores, and economically effective primarily
through a reduction in drug requirements and delay in
nursing care costs.72–74
From the evidence available, surgical management
of PD alone or in combination with medical therapy
offers the potential for greater improvement of motor
symptoms and quality of life than medical treatment
alone. DBS is now an established therapy for PD and
has an endorsed safety profile. Therefore, an important
issue is whether DBS should be considered earlier in the
course of the disease to maintain and preserve function
rather than rescue the patient. This is especially true in
aspects of life such as employment, family roles, and
social interaction.
Evidence for Earlier Use of DBS for
Symptomatic Benefit in PD
Those in favor of commencing DBS before drug-induced
motor complications become established argue that
patients would benefit sooner from improved motor
symptoms and quality of life. Opponents state that DBS
has potentially serious risks associated with it and there-
fore should not be used except as a last resort. There are
currently no strict criteria defining “early” DBS. Most
groups consider it in terms of disease severity, treatment-
related complications, and disability rather than as a
time-dependent process. As research into DBS at differ-
ent stages of PD evolves, it is possible that specific
motor, nonmotor, and functional criteria for early DBS
will emerge.
There is a modest volume of level 2 evidence that
addresses the symptomatic benefits of early DBS
(Table 2). A prospective randomized trial of early DBS
(PD duration mean5 2.1 years) in 30 patients has been
commenced and at 3 months reports that surgical com-
plication rate and lead placement were not significantly
different in the early DBS group and were in keeping
with reported data.75 In a randomized trial addressing
the symptomatic effects of bilateral STN DBS in 10
patients with early PD (defined according to duration of
disease and UPDRS III score) compared to 10 matched
medically treated controls,76 a significant benefit from
DBS on quality of life, motor signs, reduced motor com-
plications, and L-dopa requirement was observed.68 The
side effects of DBS were reported as temporary and
mild. This study, although small, highlights the clinical
benefits and safety profile of early use of DBS in relief of
motor symptoms. In terms of disadvantages of DBS, a
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separate study on the same group of patients reports that
patients with DBS experienced long-term psychosocial,
family, and professional difficulties, elements of which
were already present preoperatively.77 It is known that
poor preoperative affective state may predict continued
depression post-DBS.78
There are a number of small anecdotal reports of
DBS in early PD. For instance, a class 4 evaluation of
bilateral STN stimulation performed in the earlier and
later stages of PD, defined by disease duration and func-
tion, found that earlier DBS resulted in significantly
greater postoperative independence as assessed by ADL.79
The multicenter EARLYSTIM trial comparing early DBS
a mean of 7.5 years after diagnosis with best medical
therapy80 has recently been published.81 STN was per-
formed in 120 PD patients and compared to 127
patients in the medical therapy group. Mean age was 52
years, L-dopa therapy duration was 4.9 years, and fluctu-
ations and/or dyskinesias had been present for 1.5 or 1.7
years, respectively. The primary endpoint was quality of
life at 24 months as determined by the Parkinson’s Dis-
ease Questionnaire (PDQ)239, and showed an 8-point
difference in favor of the STN group. PDQ-39 benefit
in the STN group was evident at 5 months, with a 10-
point improvement over medical therapy. There were
additional benefits for the STN group in relation to
motor function, ADL, and L-dopa–related motor com-
plications. Serious adverse events occurred in 54.8% of
the STN group (17.7% device-related) and 44.1% of the
medical group. Those related to surgery or the device
resolved completely with the exception of 1 that left a
cutaneous scar. There were 2 suicides in the STN group
and 1 in the medical therapy group, but overall there
was no difference between the groups in suicidal
behavior.
Evidence for the economic benefit of early DBS
comes from a recent Markov state transition decision
analytic model of STN DBS applied at an early versus
delayed stage, defined by off time.82 This analysis con-
cluded that early DBS increases quality-adjusted life years
and reduces treatment costs; the need for further clinical
trials in this area was supported. There may be scope to
identify specific subgroups that are likely to have long-
term symptomatic benefit from early DBS and for these
patients to be referred to a specialist center for evalua-
tion. From the evidence available, such groups may
include young patients, those with rapidly progressive
disease, those with treatment-related complications, those
who have been confirmed to have sustained L-dopa–re-
sponsive pathology with other forms of PD excluded,
medication-intolerant patients, those with unilateral dis-
ease, and active elderly patients.82,83
One of the longest follow-up studies of DBS in PD
showed that at 10 years the effect of DBS was main-
tained in all motor domains except axial symptoms,
which negated some of the overall motor benefit.39 Bene-
fits in the domain of ADL may not be maintained
beyond 9 years of follow-up.38 There is some evidence of
late cognitive decline in patients with DBS, but this may
simply reflect disease progression.14,38 However, there
FIGURE 1: Treatment pathways in Parkinson disease (PD) and the potential role of deep brain stimulation (DBS). The optimal
treatment of PD evolves as the disease progresses. The figure shows a generally accepted paradigm for management (brown
boxes). The current role for DBS is most commonly accepted for those PD patients with significant motor complications that
limit quality of life, but whose other features (eg, L-dopa responsiveness, intact cognition) render them suitable for considera-
tion of this therapy. We propose that DBS be considered earlier in the therapeutic program of PD (green boxes), when
patients might be able to derive greater long-term benefit. COMT5 catechol-O-methyltransferase; MAO-B5monoamine
oxidase B. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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have been no comparisons to best medical therapy with
respect to the changes in ADL function expected over
this period of time.
Evidence for Earlier Use of DBS for Disease
Modification in PD
Slowing the progression of PD is a major goal of therapy,
but presents obvious significant challenges, mainly related
to the complex etiology of the disease.84–86 There has
been some evidence suggesting that STN DBS may have
a disease-modifying role in animal models of PD, but a
major limitation of these results is lack of reproducibility
in humans. This may in turn be due to the limitations
of the 6-hydroxydopamine (6-OHDA) and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of
PD in reflecting the pathophysiological mechanisms, the
differing time course of disease development, and the
effects of medication in humans.
In a 6-OHDA rodent model of PD with up to
75% of nigral neurons lost and up to 93% reduction in
dopamine levels, STN DBS prevented further neuronal
loss.87 This study also demonstrated that despite appa-
rent neuroprotection, striatal dopamine levels were not
increased. The authors highlight the role of this study in
suggesting that DBS may have benefit in early PD when
fewer neurons have been lost. There is no research yet
into the critical mass of neurons at which DBS might be
most effective and below which it could have limited
scope to work. The neuroprotective effect of STN DBS
in the rat model has also been demonstrated by other
groups88,89; STN lesioning in the 6-OHDA rat model of
PD resulted in 1=3 of nigral neurons being preserved.
90
In the hemiparkinsonian MPTP primate model,
STN DBS significantly increases striatal dopamine levels,
attenuates loss of dopaminergic cells in the periaqueduc-
tal gray matter of primates, and leads to a mean of 20%
more nigral neurons with symptomatic improvement.91–
93 The mechanisms by which DBS could mediate neuro-
protection are unknown, but have been proposed to
include a reduction in excitotoxically induced damage.92
Because advanced PD is associated with probably
>85% nigral cell death and early PD with approximately
50% cell death,94 it is probable that significant changes
to neural networks have already been established even
before the patient presents clinically.95–100 It is possible
that DBS applied to mild rather than advanced PD will
have a head start, because there are more neurons avail-
able at baseline to act upon. There is a parallel hypothe-
sis to this in terms of early initiation of medical therapy
in PD and its potential for beneficial plastic changes in
basal ganglia circuitry.101
There are few human studies examining whether
DBS has any disease-modifying effects in PD. An 18F-
fluorodeoxyglucose (FDG) PET study in 17 patients
showed no slowing of the progression of PD, suggesting
that DBS may not afford any neuroprotection.102,103
More optimistic results come from another study using
[11C] raclopride PET, which found that STN DBS
raised striatal dopamine levels and further increased levels
after L-dopa administration in patients experiencing the
wearing off phenomenon.104 This study may have been
limited because duration of DBS withdrawal before clini-
cal evaluation was only 30 to 40 minutes. However, PD
signs may become progressively worse over a span of
hours after switching off the stimulation,105 and sudden
failure of the DBS battery in PD patients has been
reported as an emergency condition, due to severe relapse
of symptoms.106
If any neuroprotective properties of DBS are lim-
ited to dopaminergic neurons, L-dopa–resistant motor
and nonmotor symptoms are unlikely to be DBS-respon-
sive.107 However, there is recent evidence on FDG PET
in advanced PD that DBS-induced effects of metabolism
extend to include cerebellar and limbic nuclei and frontal
lobes.108,109 This suggests that DBS may modulate non-
dopaminergic networks, which may in the long term
impact nonmotor clinical features of PD.
Nevertheless, the most recent long-term follow-up
studies with 5 to 10 years of continuous STN DBS have
failed to indicate a nondopaminergic neuroprotective
benefit from DBS. Patients who had STN DBS in situ
for 8 to 10 years had maintenance of motor benefits and
functional improvement despite reduction in L-dopa
dose, but had significant decline in postural stability,
axial symptoms, and a nonsignificant decline in cogni-
tion.39 The conclusions from long-term follow-up studies
suggest that the greatest sources of disability in late-stage
PD, including drug-resistant axial motor features, psychi-
atric disorders, dysautonomia, and cognitive decline, are
probably not significantly modified by DBS.110 An edi-
torial discussing a 9-year follow-up of DBS in PD high-
lights that its role may shift if there is success in the
development of disease-modifying medical therapies that
treat dopamine deficiency but do not induce the dis-
abling motor complications that currently are the strong-
est indication for DBS.111
Future Directions
Evidence is emerging that DBS may be suitable for use
in less advanced PD, at an earlier stage of disease than it
is currently commonly applied. This proposal is sup-
ported by the results of the EARLYSTIM trial. DBS
should be considered and discussed with the patient
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when the burden of the disease begins to have an impact
on the quality of life and medical therapy fails to provide
adequate control or causes significant side effects. The
improving short- and long-term safety profile of DBS
makes earlier application a realistic possibility; centers
that might consider this approach must conduct regular
prospective evaluations of their outcomes, including both
clinical benefit and adverse effects.
Conclusion
The treatment of PD has evolved significantly since the
introduction of L-dopa 40 years ago. Advances in our
understanding of the natural history of the disease and
the therapies available for its management require us
periodically to reappraise our strategies for patients.91
Advances in surgical techniques, brain imaging, and de-
vice design have brought us to the position where we
should re-evaluate which patients we can consider for
DBS and at what point in their disease this is offered.
We may be entering a period when DBS is considered
earlier in the disease course than has hitherto been
the case.
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